Context.—Controversies and uncertainty persist in prostate cancer grading. Objective.—To
update grading recommendations. Data Sources.—Critical review of the literature along with …

The combined clinical and molecular heterogeneity of prostate cancer necessitates the use
of prognostic, predictive, and diagnostic biomarkers to assist the clinician with treatment …

Intraductal carcinoma of the prostate (IDC-P) is a lethal prostate cancer subtype that
generally coexists with invasive high-grade prostate acinar adenocarcinoma (PAC) but …

Early detection of endometrial cancer, especially its precancers, remains a critical and
evolving issue in patient management and the quest to decrease mortality due to …

Abstract Background An important fraction (>/~ 10%) of men with high‐risk, localized
prostate cancer and metastatic prostate cancer carry germline (heritable) pathogenic and …

The fifth edition of the WHO Classification of Tumours of the Urinary and Male Genital
Systems encompasses several updates to the classification and diagnosis of prostatic …

Prostate cancer (PCa) has a distinct molecular signature, including characteristic
chromosomal translocations, gene deletions and defective DNA damage repair …

Simple Summary Intraductal carcinoma of the prostate (IDC-P) is a neoplastic proliferation
within the prostatic ducts with a retained basal cell layer that exceeds the usual extent of …

While localised prostate cancer can be cured by local treatment,'high-risk'prostate cancer
often progresses to castration resistant disease and remains incurable with a dismal …

Intraductal carcinoma of the prostate (IDC-P) has been recently recognized by the World
Health Organization classification of prostatic tumors as a distinct entity, most often occurring …